- Newsletter
- May 2024
Global
From €1010EUR$1,132USD£889GBP
- Report
- November 2023
- 175 Pages
Global
From €4778EUR$5,000USD£4,066GBP
- Report
- May 2024
- 138 Pages
Global
From €6211EUR$6,499USD£5,284GBP
- Report
- March 2024
- 150 Pages
Global
From €4960EUR$5,190USD£4,220GBP
- Report
- December 2023
- 150 Pages
Global
From €3472EUR$3,633USD£2,954GBP
€4960EUR$5,190USD£4,220GBP
- Clinical Trials
- April 2024
- 100 Pages
Global
From €2867EUR$3,000USD£2,439GBP
- Report
- November 2023
- 432 Pages
Global
From €9079EUR$9,500USD£7,725GBP
- Report
- January 2021
- 600 Pages
United States
From €2274EUR$2,380USD£1,935GBP
€2676EUR$2,800USD£2,277GBP
- Report
- November 2020
- 124 Pages
Global
From €1147EUR$1,200USD£976GBP
- Report
- January 2022
- 160 Pages
Global
From €9079EUR$9,500USD£7,725GBP
- Clinical Trials
- November 2020
- 40 Pages
Global
From €1433EUR$1,500USD£1,220GBP
- Report
- November 2021
- 40 Pages
China
From €2485EUR$2,600USD£2,114GBP
- Report
- May 2021
- 50 Pages
China
From €2485EUR$2,600USD£2,114GBP
- Report
- March 2021
- 94 Pages
Global
€21024EUR$22,000USD£17,889GBP
- Drug Pipelines
- January 2018
- 21 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Drug Pipelines
- January 2018
- 18 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Drug Pipelines
- January 2018
- 17 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Report
- August 2019
- 212 Pages
Global
From €10507EUR$10,995USD£8,940GBP
Abiraterone is a drug used to treat prostate cancer. It is a type of hormone therapy, which works by blocking the production of testosterone, a hormone that can fuel the growth of prostate cancer cells. Abiraterone is typically used in combination with other treatments, such as chemotherapy or radiation therapy. It is usually prescribed to men with advanced prostate cancer that has spread to other parts of the body. Abiraterone is available in both oral and injectable forms.
Abiraterone has been shown to be effective in treating prostate cancer, and is generally well-tolerated by patients. Common side effects include fatigue, joint pain, and hot flashes. Abiraterone is also associated with an increased risk of high blood pressure and fluid retention.
Companies in the Abiraterone market include Janssen Pharmaceuticals, Astellas Pharma, and Teva Pharmaceuticals. Show Less Read more